Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,006 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S. Shimizu K, et al. Among authors: matsushita h. Cancer Res. 2013 Jan 1;73(1):62-73. doi: 10.1158/0008-5472.CAN-12-0759. Epub 2012 Oct 29. Cancer Res. 2013. PMID: 23108144
[Dendritic cells for cancer immunotherapy].
Kakimi K, Kondo A, Matsushita H. Kakimi K, et al. Among authors: matsushita h. Nihon Rinsho. 2012 Dec;70(12):2130-5. Nihon Rinsho. 2012. PMID: 23259385 Review. Japanese.
Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K. Izumi T, et al. Among authors: matsushita h. Cytotherapy. 2013 Apr;15(4):481-91. doi: 10.1016/j.jcyt.2012.12.004. Epub 2013 Feb 5. Cytotherapy. 2013. PMID: 23391461 Clinical Trial.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Wada H, et al. Among authors: matsushita h. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. J Immunother. 2014. PMID: 24509171 Clinical Trial.
1,006 results